AstraZeneca Resets FTC Review Clock For $39B Alexion Deal
AstraZeneca PLC is resetting the clock to give the Federal Trade Commission more time to review its roughly $39 billion bid for Alexion Pharmaceuticals Inc., the latter company disclosed Monday....To view the full article, register now.
Already a subscriber? Click here to view full article